Bree Foster, PhD
Bree Foster is a science writer at Drug Discovery News with over 2 years of experience at Technology Networks, Drug Discovery News, and other scientific marketing agencies. She holds a PhD in comparative and functional genomics from the University of Liverpool and enjoys crafting compelling stories for science.
Articles by Bree Foster, PhD
| 8 min read
Live-cell assays using BRET offer a sensitive and scalable approach for studying small molecule and biologic interactions in real time.
| 4 min read
A new bacterial platform can produce millions of stabilized peptides in a single experiment, accelerating the search for therapies against hard-to-drug targets.
| 4 min read
Machine learning helps translate complex DNA fragment patterns into disease-specific signatures, offering a new path for early detection.
| 4 min read
Neflamapimod shows promise in slowing ALS by targeting protein clumps and restoring nerve cell function.
| 4 min read
Wake Forest researchers have reprogrammed macrophages to target metastatic tumors in the brain, offering a potential new approach where conventional therapies struggle.
| 4 min read
Researchers uncover how microbes targeting the colon’s mucus may explain treatment-resistant constipation in Parkinson’s disease and other patients.
| 4 min read
AI and high-throughput functional screening helped researchers design antibodies that selectively activate CB2, reducing inflammation and scar tissue in human liver tissue.
| 4 min read
High-throughput T-cell receptor sequencing reveals shared immune signatures in celiac disease, opening the door to earlier, less invasive diagnosis and disease monitoring.
| 4 min read
Emerging clinical trials suggest that the gut microbiome plays a decisive role in how patients respond to immunotherapy.
| 5 min read
A new model combines high-resolution experimental data with deep learning to reveal how non-coding DNA sequences control gene activity across different cell types.
| 4 min read
By separating therapeutic neuroplasticity from hallucinations, new psychedelic-inspired molecules could make treatment safer and more accessible.
| 5 min read
Researchers identify how levetiracetam keeps neurons from producing harmful amyloid-beta, pointing to new ways to intervene before Alzheimer’s symptoms appear.
